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Abstract
As secondary complications remain a significant cause of morbidity and mortality amongst hospitalised trauma
patients, the need to develop novel approaches by which to identify patients at risk of adverse outcome is becoming
increasingly important. Centred on the idea that patients who experience “poor” outcome post trauma elicit a
response to injury that is distinct from those who experience “good” outcome, tailored therapeutics is an emerging
concept aimed at improving current treatment regimens by promoting patient-specific therapies. Making use of recent
advancements in the fields of genomics, proteomics and metabolomics, numerous groups have undertaken a systems-
based approach to analysing the acute immune and inflammatory response to major traumatic and thermal injury in
an attempt to uncover a single or combination of biomarkers that can identify patients at risk of adverse outcome.
Early results are encouraging, with all three approaches capable of discriminating patients with “good” outcome from
those who develop nosocomial infections, sepsis and multiple organ failure, with differences apparent in blood
samples acquired as early as 2 h post injury. In particular, genomic data is proving to be highly informative, identifying
patients at risk of “poor” outcome with a higher degree of sensitivity and specificity than statistical models built upon
data obtained from existing anatomical and physiological scoring systems. Here, focussing predominantly upon
human-based research, we provide an overview of the findings of studies that have investigated the immune and
inflammatory response to major traumatic and thermal injury at the genomic, protein and metabolite level, and
consider both the diagnostic and prognostic potential of these approaches.
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Background
Despite recent advancements in the fields of fluid resus-
citation and coagulopathy, traumatic injury remains the
cause of more than five million deaths worldwide per
year [1]. Moreover, those who survive the initial trauma
are at an increased risk of multiple organ failure (MOF),
acute respiratory distress syndrome (ARDS), nosocomial
infections and sepsis, secondary complications that are
associated with a range of adverse outcomes that include
an extended length of intensive care unit (ICU) and
hospital stay and an increased risk of death [2–6]. One
factor thought to underlie these high mortality and
morbidity rates is the trauma-induced alteration to im-
mune and inflammatory responses. For instance, exag-
gerated immune and inflammatory reactions in the
immediate aftermath of trauma are considered a con-
tributory factor in the development of early MOF, whilst
a state of immune paralysis, which develops in the days
following injury, is viewed as a major factor underlying
the increased susceptibility of trauma patients to
hospital-acquired infections [7, 8].
In the settings of critical illness, traumatic brain injury
(TBI) and blunt trauma, significant relationships have
been reported between the immune response to injury
and patient outcome. Trauma-induced alterations in the
frequency, phenotype and/or function of circulating neu-
trophils, monocytes, natural killer cells and lymphocytes
have been shown to be associated with patient mortality,
increased length of hospital stay and the onset of such
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secondary complications as sepsis and ARDS (Table 1).
However, there is little evidence to suggest that these as-
sociations are of any diagnostic or prognostic value.
Thus, in recent years, with the aim of improving patient
care, the emphasis of much trauma research has
switched to biomarker discovery. Utilising the recent
technological advancements in the fields of genomics,
proteomics and metabolomics, several groups have per-
formed detailed systems-based analysis of the immune
and inflammatory response to major traumatic and ther-
mal injury in an attempt to identify a single or combin-
ation of biomarkers that are of diagnostic and/or
prognostic significance [9–13]. One of the long-term
goals associated with this research is to reduce trauma-
related morbidity and mortality rates via the implemen-
tation of patient-specific treatment and management
protocols. Early results are encouraging, with genomic
data providing information that in some instances has
outperformed existing anatomical and physiological
scoring systems in highlighting those trauma patients at
risk of “poor” outcome [14, 15]. In this review, we sum-
marise the findings of studies that have investigated the
immune and inflammatory response to major traumatic
and thermal injury at the genomic, protein and metabol-
ite level, and consider the diagnostic and prognostic
potential of these approaches. Given the differences that
have been described in the immune/inflammatory re-
sponse to severe injury between mice and humans [16],
and the ongoing debate as to how closely murine models
of trauma mimic the human response to injury [17–19],
the findings discussed in this review, unless otherwise
stated, have been generated from human-based studies.
Review
The genomic response to major traumatic injury
A technique that involves the mapping and sequencing
of genes, genomics is a field of systems-based research
that provides information on gene expression in a par-
ticular cell/tissue at any given time. Our current under-
standing of the genomic response to major traumatic
injury is derived almost entirely from the findings of a
large-scale collaborative research programme entitled
“Inflammation and the Host Response to Injury”, in
which genome-wide expression analysis has been per-
formed on circulating leukocytes obtained from adults
following either severe blunt trauma or thermal injury
[14, 15, 20–24].
In a seminal paper published in 2011, Xiao and col-
leagues described altered expression of >80 % of the
leukocyte genome following severe blunt trauma [22].
Referred to as a “genomic storm”, a total of 5136 genes
exhibited a ≥two-fold change in expression relative to
healthy controls, with pathway analysis revealing signifi-
cant trauma-induced increases in the expression of
genes involved in innate immunity, pathogen recognition
and inflammation that occurred concomitant with
Table 1 Trauma-induced changes in immunity that are associated with and/or predictive of adverse patient outcomes
Increased risk of nosocomial
infection
Development of sepsis Mortality
Neutrophils Frequency Increased [60]








Monocytes Frequency Decreased [60]
Phenotype Decreased HLA-DR [80, 86] Decreased HLA-DR [61, 87–89] Decreased HLA-DR [88]
Increased intracellular TLR9
expression [33]





Leukocytes Frequency Increased [60] Increased [93]
Gene expression Increased expression of
inflammation-related genes
[15, 22]
Increased P38 MAPK and IL-6
expression [22, 23]
Decreased expression of genes
related to antigen presentation
and T cell regulation [15, 22, 23]
Lymphocytes Frequency Decreased [60, 93] Decreased [93]
Abbreviations: HLA-DR human leukocyte antigen-DR, IL-6 interleukin-6, LPS lipopolysaccharide, MAPK mitogen-activated protein kinase, TLR toll-like receptor, TNF
tumour necrosis factor alpha
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reduced expression of genes related to antigen presenta-
tion and T cell function [22]. Time wise, whilst the
greatest changes in gene expression were observed in
samples obtained within 12 h of trauma, altered ex-
pression was still evident in leukocytes acquired
28 days post-injury, demonstrating that major blunt
trauma is associated with both a rapid and prolonged
genomic response [22].
Whilst clinical parameters such as injury severity score
(ISS), blood transfusion and base deficit have little or no
impact upon gene expression profiles post-trauma [22],
patient age has been shown to strongly influence the
genomic response to injury. Splitting a cohort of 244
severely-injured blunt trauma patients into young
(<55 years) and old (≥55 years) sub-groups, Vanzant et
al. reported significant age-associated differences in both
the magnitude and duration of the genomic response to
injury [24]. The group demonstrated that during the
acute phase of injury (12–24 h), gene expression pat-
terns of neutrophils isolated from younger adults were
significantly more perturbed, relative to healthy controls,
than those of older adults [24]. However, in the sub-
acute period (day 4 post-injury), the reverse was ob-
served, with the gene expression profiles of neutrophils
from aged donors significantly more different from con-
trol subject values than those recorded for younger pa-
tients [24]. Thus, older adults elicit a unique genomic
response to severe injury that is defined by an initial at-
tenuated response that takes longer to return to a
homeostatic baseline. Interestingly, with the exception of
the work of Vanzant and colleagues [24], all studies pub-
lished to date that have investigated the genomic re-
sponse to trauma have analysed samples collected from
patients aged 16–55 years [14, 15, 20–23]. Thus, it is
currently unclear as to what ramifications, if any, the
data of Vanzant et al. [24] will have for the proposed use
of genomics as a prognostic indicator of patient outcome.
It may be that separate cohorts of healthy young and older
adults are needed in order to serve as age specific refer-
ence ranges to which the genomic profiles of traumatically
injured young and geriatric patients would be compared.
Alternatively, an approach in which patients serve as their
own internal controls for gene expression changes could
be adopted. This strategy of studying “within-patient gene
expression changes” (WPEC), which involves quantifying
per-hour log-fold changes in gene expression in the post-
injury phase, has proven successful in a cohort of blunt
trauma patients, where WPEC were strongly associated
with long-term post-injury complications [23].
The genomic response to major trauma and its relationship
with patient outcome
Several studies have shown that in the immediate hours
and days following major traumatic injury, gene
expression profiles of circulating leukocytes differ be-
tween patients who experience “good” outcome and
those who report “poor” outcome. Interestingly, it is the
magnitude and duration of the genomic response rather
than the directional changes in gene expression that dis-
criminate these two groups from one another [14, 20,
22]. Indeed, relative to healthy controls, both groups
elicit a genomic response that is characterised by the up-
regulation of genes involved in cytokine production and
the synthesis/degradation of inflammatory lipid media-
tors, and the down-regulation of genes related to antigen
presentation and T cell function [20, 22]. However, pa-
tients with complicated recovery (defined as recovery
>14 days, no recovery or death) display a unique kinetic
profile that is defined by more robust early changes
(<12 h post-injury) in gene expression that fail to return
to a homeostatic baseline as quickly as that observed in
patients who report “good” outcome [20, 22]. Moreover,
the further the genomic profile of a patient differs from
that of a control, the more likely they are to develop
nosocomial infections and experience longer lengths of
both ICU and hospital stay [21]. Importantly, these asso-
ciations remained after controlling for the effects of in-
jury severity and physiological dysfunction [21].
Data are beginning to emerge suggesting that early
genomic profiling may have potential as a highly sensi-
tive prognostic tool for the identification of trauma pa-
tients at risk of adverse outcome. In a cohort of 96
severely-injured blunt trauma patients, Cuenca et al.
demonstrated that an assessment of leukocyte gene ex-
pression within 24 h of injury could differentiate patients
who experienced a complicated recovery from those
with an “uneventful” outcome, with an area under the
receiver operator curve (AUROC) value of 0.811 [14].
Similarly, in a group of thermally-injured patients, gen-
omic scoring correctly predicted the development of
multiple hospital-acquired infections in 80 % of patients
[15]. Interestingly, in both studies, models built on gen-
omic analysis outperformed the predictive capabilities of
models based on clinical, anatomical and physiological
data [14, 15], suggesting that genomic analysis provides
unique information on a patients response to traumatic
injury that supersedes the prognostic capacity of current
scoring systems.
Given that >80 % of the leukocyte transcriptome is al-
tered post-trauma, changes in a single or subset of genes
are unlikely to emerge as biomarkers for the identifica-
tion of patients at risk of poor outcome [22]. Rather, it
will be information derived from the assessment of
changes in global gene expression that will form the
basis of any future prognostic models developed on the
back of genomic data. On this note, mathematical sys-
tems have been developed that can simplify changes that
occur in gene expression across the entire genome into
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a single number. This approach has been applied to
trauma studies and proven successful in identifying
those patients who experience “poor” outcome [14, 21].
However, the major drawback of these studies as well as
those described above is that all genomic data has been
derived from and tested within patients recruited as part
of a single trauma study, namely the Inflammation and
the Host Response to Injury programme [14, 15, 20–24].
Thus, until these data and the associated scoring systems
have been tested and validated in independent cohorts of
trauma patients, its suitability as a prognostic indicator of
patient outcome should be viewed with caution [25].
The prognostic value of mitochondrial DNA
The systemic inflammatory response syndrome (SIRS)
that occurs in the immediate aftermath of major trau-
matic injury is thought to be triggered in part by the re-
lease from damaged, stressed or necrotic tissue of
damage associated molecular patterns (DAMPs). A col-
lection of cytosolic, nuclear and mitochondrial-derived
proteins and DNA, DAMPs activate circulating immune
cells via interaction with pathogen recognition receptors
(PRRs), which include members of the toll-like receptor
(TLR) family [26] (Fig. 1).
DAMP release has been proposed as a mechanistic ex-
planation for the near identical gene expression profiles
reported for leukocytes isolated from severe blunt and
thermally-injured patients [22]. Although markedly dif-
ferent in their mechanism of injury, it has been sug-
gested that both blunt and thermal trauma leads to the
release into the circulation of DAMPs, whose subse-
quent PRR-mediated activation of leukocytes triggers a
common genomic response [22]. Aside from genomics,
we have recently shown mitochondria-derived DAMPs
to be potent inducers of interleukin (IL)-8 secretion by
human neutrophils in vitro [27], whilst others have dem-
onstrated in vivo administration of mitochondrial DNA
(mtDNA) triggers an inflammatory response in rats that
resembles many facets of the SIRS response observed in
traumatically-injured humans [28, 29]. Thus, if capable
of influencing both the genomic and inflammatory re-
sponse to injury, could a measurement of circulating
DAMPs provide information that is of prognostic
significance?
In TBI subjects [30] and cohorts of mixed trauma pa-
tients [31, 32], a measurement of circulating mtDNA
levels at hospital admission or in the days following in-
jury has identified patients at risk of poor outcome. Sig-
nificantly higher levels of mtDNA have been reported in
plasma and cerebrospinal fluid samples from subjects
who subsequently developed SIRS/MOF during their
hospital stay or who exhibited poor functional outcome
at follow up [30, 31]. Furthermore and of particular
interest, three studies have demonstrated a relationship
between mtDNA and patient survival, with the levels of
this DAMP significantly elevated in the samples of non-
survivors compared to survivors [30, 32, 33]. In terms of
potential clinical relevance, inclusion of mtDNA levels
into a scoring system that contained information on
patient physiology and gender was shown to signifi-
cantly improve the power of this model in discrimin-
ating survivors from non-survivors, suggesting that an
early assessment of mtDNA levels may be of prognos-
tic benefit [33].
Rich in unmethylated CpG motifs, mtDNA is recog-
nised by the PRR TLR9 [29]. In a prospective observa-
tional study of critically-ill patients, Krychtiuk et al.
found no significant difference in the intracellular ex-
pression levels of TLR9 in monocytes between survivors
and non-survivors [33]. However, when analysed in the
context of mtDNA levels, TLR9 was found to be a sig-
nificant predictor of survival in patients with “high” but
not “low” plasma levels of mtDNA [33]. Related to this,
the group also showed mtDNA was only significantly as-
sociated with mortality in those patients they defined as
possessing “high” intracellular levels of TLR9 [33]. Thus,
unsurprisingly, patients stratified as “high” for both
plasma mtDNA and TLR9 expression exhibited the
greatest risk of death within 30 days of hospital admis-
sion [33]. Mechanistically, this relationship between
mtDNA, TLR9 and mortality has been proposed to re-
flect a mtDNA-driven hyper activation of the innate im-
mune system [33].
Taken together, these data suggest that either in isola-
tion or in combination with other clinical assessments, a
measure of mtDNA levels and its receptor TLR9 in the
early phase post-injury provides information that has the
potential to assist in the identification of patients at in-
creased risk of poor outcome.
MicroRNA screening as a tool for the early diagnosis and
stratification of traumatic injury
MicroRNAs (miRNAs) are a highly conserved class of
short single-stranded non-coding RNA molecules, which
via translational repression or degradation of messenger
RNA play an important role in regulating gene expres-
sion [34]. In rodents [35–37] and humans [38, 39], trau-
matic injury leads to significant alterations in the
circulating levels of miRNAs. For instance, when com-
pared to healthy controls, the levels of circulating miR-
NAs predicted to regulate the expression of pro- and
anti-inflammatory cytokine genes (e.g., miR-125a, miR-
181, miR-202, miR-374b and miR454) as well as genes
involved in neuronal survival and central nervous system
signalling have been shown to be increased or decreased
in samples obtained post-polytrauma or TBI [36, 38].
On current evidence, miRNA screening appears to
hold promise as a tool for both the diagnosis of TBI and
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the stratification of these patients according to injury se-
verity [35, 36, 39]. Compared to the values of healthy
subjects, decreased levels of miR-16 and miR-92a, and
increased levels of miR-765 have been reported in
plasma samples acquired from severe TBI patients 24–
48 h post-injury [39]. Whilst as single entities, miR-16,
miR-92a and miR-765 were considered good markers of
severe TBI (AUROC values of 0.89, 0.82 and 0.86 re-
spectively), in combination these miRNAs discriminated
with 100 % sensitivity and 100 % specificity severe TBI
Fig. 1 Damage Associated Molecular Patterns (DAMPs) release and immune cell activation following sterile traumatic injury. Tissue damage
arising from traumatic or thermal injury results in the release into circulation of mitochondrial (e.g. mtDNA, formyl peptides), cytosolic (e.g. F-actin) and
nuclear (e.g. HMGB1)-derived damage associated molecular patterns (DAMPs). Through binding to pathogen recognition receptors, DAMPs trigger the
activation of circulating immune cells resulting in the secretion of pro- and anti-inflammatory cytokines as well as a series of functional responses,
which include the generation of reactive oxygen species (ROS) and neutrophil extracellular traps (NETs). Together, cell activation and cytokine secretion
creates an inflammatory environment that favours the development of multiple organ failure, tissue damage and immunoparesis, conditions that are
associated with a range of poor patient outcomes, which include a longer length of hospital stay and an increased risk of sepsis and mortality. Tissue
damage arising from immune cell activation would lead to the release of further DAMPs, creating a vicious cycle, with continued inflammation and
immune activation. ATP adenosine tri phosphate, DAMP damage-associated molecular pattern, F-actin filamentous actin, HMGB1 high-mobility group
box 1 protein, IL interleukin, LOS length of stay, MCP-1 monocyte chemoattractant protein 1, MOF multiple organ failure, mtDNA mitochondrial DNA,
NETs neutrophil extracellular traps, ROS reactive oxygen species, SIRS systemic inflammatory response syndrome, TNF-α tumour necrosis factor-alpha
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patients from controls [39]. Similarly, significant differ-
ences have been found in the serum levels of 13 miR-
NAs between sham mice and those subjected to
differing degrees of mild TBI (mTBI) [36]. Given the
lack of immediate symptoms associated with mTBI,
miRNA profiling may be a useful tool by which to im-
prove upon the current methods of diagnosis, which re-
volve around the interpretation of imaging data and
clinical examination [36].
Aside from the diagnosis of TBI, miRNA profiling may
assist in the identification of those trauma patients at an
increased risk of hospital-acquired infection. Measuring
circulating miRNA levels in samples acquired from 30
polytrauma patients upon hospital admission and 24 h
post-injury, Owen et al. found significantly lower levels
of miR-125a and miR-374b in samples from patients
who subsequently developed pneumonia [38]. Predicted
to target IL-10 mRNA, it was suggested that decreased
levels of miR-125a and miR-374b could increase patient
susceptibility to infection by creating an immune sup-
pressive environment [38]. On this note, in a larger co-
hort of polytrauma patients, the group had previously
reported elevated IL-10 mRNA levels at 24 h post-injury
were associated with the development of bacteraemic
episodes [40].
The inflammatory response to major traumatic injury
Two distinct responses characterise the immune and in-
flammatory reactions to major traumatic injury; a systemic
inflammatory response, defined by elevated levels of circu-
lating pro-inflammatory cytokines and immune cell acti-
vation, and a compensatory anti-inflammatory response
characterised by increased levels of anti-inflammatory cy-
tokines and immunoparesis [41]. For many years, it was
thought that these two responses were sequential. How-
ever, at both the transcript [22] and protein [10, 42, 43]
levels, data has recently emerged that challenges this long-
standing paradigm, with evidence of a simultaneous in-
crease in pro- and anti-inflammatory responses post-
trauma. Indeed, across a range of trauma cohorts, elevated
levels of pro- and anti-inflammatory cytokines have been
measured in samples obtained 2–24 h post-injury [10, 42,
43]. Faced with these data, numerous groups have investi-
gated whether patients that elicit a more robust inflamma-
tory response to trauma are at an increased risk of adverse
outcome (Table 2).
Cytokines and their relationship with patient outcome
Mortality and MOF In burns research, several studies
have shown that a measure of circulating inflammatory
cytokines and chemokines in the early post-injury phase
can distinguish survivors from non-survivors. In cohorts
of paediatric and adult patients, elevated levels of
interleukin IL-6, IL-8, IL-10, IL-15, monocyte chemo-
attractant protein-1 (MCP-1), granulocyte-colony stimu-
lating factor (GCSF), IL-1 receptor antagonist (IL1-RA)
and eotaxin as well as reduced levels of IL-4, IL-7 and
IL-13 have been detected in plasma/serum samples of
non-survivors compared to survivors [10, 11, 44–47].
These differences, which are evident in samples acquired
at hospital admission and/or days three and seven post-
trauma, suggest that an immediate assessment of the
inflammatory response to thermal injury may have prog-
nostic value. Importantly, elevated levels of cytokines
remain significantly associated with mortality after con-
trolling for factors known to increase the risk of death
post-burn injury such as patient age, percent total body
surface area (TBSA) burned and inhalation injury [45,
47]. Furthermore, and of particular interest, Finnerty et
al. showed in a cohort of 330 paediatric patients with
>25 % TBSA burn that combining measurements of cir-
culating cytokines with clinical information improved
the predictive accuracy of models built on clinical vari-
ables alone by 29 %, highlighting the benefit that the in-
clusion of laboratory-derived data can have on current
medical indicators of patient outcome [46].
Akin to thermal injury, circulating concentrations of in-
flammatory cytokines have been found to differ between
survivors and non-survivors of TBI and polytrauma, with
elevated levels of IL-6, IL-8 and/or IL-10 present in sam-
ples obtained within 24 h of injury from patients who suc-
cumb to their injuries [42, 48–50]. Of note, in a cohort of
93 patients with TBI, Soares et al. found that within 10 h
post-injury, patients with high serum IL-10 levels (>90 pg/
ml) were six times more likely to die than those with low
IL-10 levels (<50 pg/ml) independent of ISS and age [50].
Relationships between raised serum cytokines and poor
outcome post-TBI may be related in part to the role of
these inflammatory mediators in the development of sec-
ondary complications [51].
Multiple organ dysfunction syndrome (MODS) and
MOF are major secondary complications amongst hospi-
talised trauma patients that are associated with increased
mortality rates and length of hospital stay [43]. A meas-
ure of circulating inflammatory cytokines in the early
hours/days post-injury has been shown to be capable of
identifying those patients at an increased risk of MOF.
Following, major chest trauma [43], TBI [52], poly-
trauma [49] and severe injury [53], significantly elevated
levels of multiple cytokines and chemokines such as IL-
1RA, IL-6 and IL-10 have been recorded in samples ob-
tained from those patients who subsequently develop
MOF. Of these studies, Cuschieri and co-workers dem-
onstrated that a plasma concentration of IL-6 ≤ 350 pg/
ml within 12 h of severe blunt trauma could identify
with 88 % accuracy those patients who would not de-
velop MODS during their hospital stay [53].
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Nosocomial infection and sepsis Nosocomial infec-
tions and sepsis are common secondary complications
amongst hospitalised trauma patients. In thermally-
injured subjects in particular, sepsis is not only a highly
prevalent complication but a significant cause of mortal-
ity, with sepsis-related deaths in this cohort exceeding
those reported in the settings of traumatic injury and
critical care [54]. Within 24 h of burn injury, IL-6 and
IL-8 levels have been found to be significantly greater in
serum samples obtained from patients that subsequently
develop sepsis during their hospital stay when compared
to those who do not [55–58]. Furthermore, a measure of
inflammatory cytokine levels during septic episodes can
provide information on infection-related outcome. In a
study of 60 burn-injured patients, Pileri and colleagues
demonstrated that a cut-off value for IL-10 of 60 pg/ml
at day three post-injury could discriminate septic survi-
vors from non-survivors with 93 % specificity and 92 %
sensitivity [57].
In addition to thermally-injured, a measure of the in-
flammatory response following TBI and blunt trauma
can identify patients at risk of sepsis/nosocomial infec-
tion [59, 60]. Interestingly, as reported in genomic stud-
ies [14, 20, 22], it is the magnitude of the inflammatory
response that discriminates infected patients from their
non-infected counterparts, with the former group elicit-
ing a more robust inflammatory response in the immedi-
ate aftermath of injury [60].
Despite numerous studies reporting associations be-
tween circulating cytokine levels and infection, the use
of cytokine measurements as a stand-alone tool for the
early identification of sepsis is hampered by insufficient
sensitivity and specificity. Interestingly, in a recent pro-
spective observational study of 100 severely-injured
trauma patients, Cheron et al. demonstrated that com-
bining an assessment of a patient’s immune status with a
measurement of circulating IL-6 concentrations could
improve both the specificity and positive predictive value
of models built on cytokine data alone [61]. Thus, this
result highlights the potential of combining different
systems-based approaches for the development of more
accurate and reliable models for use in the diagnosis
and/or prognosis of sepsis amongst hospitalised trauma
patients.
The metabolomic response to major traumatic injury
A technique that identifies and quantifies metabolites
within biological fluids, cells and tissues, metabolomics
is a systems-based approach for the profiling and ana-
lysis of cellular processes. A long-standing interest of re-
searchers in the fields of inflammatory disease and
infection [62–67] metabolic profiling is an emerging area
of research in the settings of critical care and trauma. In
animal models of polytrauma with haemorrhagic shock
[68–73], as well as in cohorts of TBI [74], burns [75]
and major trauma [9, 12, 76, 77] patients, analysis of
blood [9], plasma [9, 12, 72, 73, 75, 76], serum [69, 71,
74], lymph [77] and urine [70, 71] collected in the hours
and days post-injury has shown severe metabolic disrup-
tion to be a consequence of trauma. For example,
marked alterations, relative to healthy controls, have
been reported in the concentrations of multiple metabo-
lites such as serine, lactate, succinate, carnitine and cit-
rate, demonstrating that trauma leads to disturbances in
carbohydrate, protein and fatty acid metabolism [9, 12,
68–77].
Besides simply describing the changes that occur in
the circulating “metabolome” post-injury, a handful of
groups have investigated whether metabolic profiling has
the potential to serve as a prognostic tool. In one of the
first studies to examine the relationship between
trauma-induced metabolic derangement and patient out-
come, Cohen et al. found in a cohort of major trauma
patients that survivors and non-survivors could be
Table 2 Examples of trauma-induced inflammatory responses that are associated with and/or predictive of adverse patient outcomes
Increased risk of nosocomial
infection
Development of sepsis Development of MODS/MOF Mortality
IL-6 Elevated levels at admission
post blunt trauma [60]
Elevated levels following
thermal injury [55, 56]
Elevated levels post severe
trauma [43, 53, 94]
Elevated in non-survivors following
thermal injury [10, 11, 45, 47] and
TBI [42]
IL-8 Elevated levels following
thermal injury [55, 56]
Elevated in non-survivors following
thermal injury [10, 45, 47] and TBI [42]
IL-10 Elevated levels post severe
trauma [43]
Elevated levels associated with
increased risk of death post thermal
injury [95] and TBI [42, 50]
IL1-RA Elevated levels at admission
post blunt trauma [60]
Elevated levels post severe
traum [43, 94]
Elevated in non-survivors following
thermal injury [11, 47]
MCP-1 Elevated levels at admission
post blunt trauma [60]
Elevated in non-survivors following
thermal injury [10, 11, 47]
Abbreviations: IL interleukin, IL1-RA interleukin 1 receptor antagonist, MCP-1 monocyte chemoattractant protein, MODS multiple organ dysfunction syndrome, MOF
multiple organ failure, TBI traumatic brain injury
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clearly discriminated by the concentrations of triacyl-
glycerol, phospholipids and monounsaturated fatty acids
in admission blood samples, with non-survivors present-
ing with significantly lower levels of all three lipid me-
tabolites [9]. Similar to these observations, Lexcen and
co-workers recently reported in a porcine model of
polytrauma and haemorrhagic shock that when com-
pared to survivors, concentrations of succinate and O-
phosphocholine were significantly increased and de-
creased, respectively, in animals that succumbed to their
injuries [69]. Aside from mortality, metabolic profiling in
the early post-injury phase may be a useful approach for
identifying patients that are at an increased risk of post
traumatic complications [74, 78, 79]. For example, in a
cohort of 22 severely-injured patients, a metabolomic as-
sessment of plasma samples acquired at admission to
ICU was found to identify with a reasonable degree of
certainty (AUROC = 0.778) patients that subsequently
developed sepsis during their hospital stay [78]. Interest-
ingly, in an independent cohort of ICU patients, Mickie-
wicz et al. recently demonstrated that a combination of
metabolomic and proteomic data could accurately dis-
criminate, with a sensitivity of 0.94 and a specificity of 1,
septic shock patients from those undergoing a SIRS re-
sponse in the absence of infection [79]. Shown to per-
form better than statistical models built on clinical
scoring systems, these data highlight the improved dis-
criminatory power that can be gained by combining
system-based approaches [79].
Although in its infancy, metabolic profiling of trauma
patients has potential prognostic utility for identifying
individuals that are at an increased risk of poor outcome.
However, given the limited number of studies and the
small size of the patients cohorts analysed, further work
is needed to not only validate published observations
but also address whether clinical (e.g. ISS) and patient
(e.g. gender, age) variables influence the metabolomic re-
sponse to injury. Furthermore, in the context of tailored
therapeutics, it will be interesting for future studies to
examine whether the circulating “metabolome” can pro-
vide information on a patients response to treatment regi-
mens (e.g. resuscitation) or therapeutic interventions,
which if proven to be the case, could lead to the imple-
mentation of patient-specific management protocols.
Conclusions
Although in its infancy, it is evident that a system-based
approach to studying the immune and inflammatory re-
sponse to severe traumatic and thermal injury has the
potential to generate data that can influence patient care.
Once laborious and time-consuming, recent techno-
logical advancements have revolutionised the practical-
ities of systems-based approaches, making it possible for
instance to perform genome-wide expression analysis
within 12–18 h [14]. By identifying with a high degree of
accuracy patients at risk of “poor” outcome, system-
based approaches have in some instances outperformed
the prognostic capacity of existing clinical scoring sys-
tems [14, 15], meaning it is conceivable that metabolo-
mic, proteomic and/or genomic data will be utilised in
the future to assist in the creation of tailored treatment
and/or management protocols. Interestingly, across mul-
tiple cohorts of patients with differing mechanisms of
injury, alterations in innate immune responses, inflam-
matory pathways and adaptive immunity have consist-
ently been linked to adverse outcome, suggesting that a
common mechanism may underlie the dysregulated im-
mune and inflammatory response of patients that experi-
ence high morbidity and mortality rates post-injury.
Investigating such mechanisms should be the focus of
futures studies, with the long-term goal of identifying
novel therapeutic targets.
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